Early results from the phase III trial of laquinimod indicate that the drug is no more effective than placebo in reducing relapses, according to a press release issued by Teva Pharmaceuticals (http://hugin.info/1002/R/1535269/468107.pdf) and an August 1st webcast to investors (http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-EventDetails&EventId=4168607). More complete results from the trial are expected to be presented later this year at the European Committee for Treatment and Research in MS (ECTRIMS) annual conference in Amsterdam.